SFRP2 and triple-negative breast carcinoma: We further discovered that SFRP2 is a novel stimulator of angiogenesis in vivo [9] and in vitro, and that antagonism of SFRP2 with a mouse monoclonal antibody inhibited triple negative breast carcinoma and angiosarcoma growth in mice [10].